Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Non-small cell lung cancer

The first targeted therapy for KRAS G12C mutation [1].

    • News
    • Oncology
    • Pneumology
    • RX
    • Studies
  • 4 minute read

After decades of effort, it is now possible for the first time to provide patients with KRAS G12C-mutated non-small cell lung cancer with an effective targeted therapy [1,2]. In the pivotal trial, the highly selective KRAS G12C inhibitor resulted in a rapid and sustained response in heavily pretreated patients [2]. The 2-year long-term follow-up also showed promising results [3].

Activating (KRAS) mutations* are the most common oncogenic driver mutations in non-small cell lung cancer (NSCLC). The most common of these is the KRAS G12C mutation, which is detectable in approximately 13% of all adenocarcinomas [2]. With the highly selective KRAS G12C inhibitor Lumykras® (Sotorasib), adult patients with locally advanced or metastatic non-squamous NSCLC with KRAS G12C mutation who have experienced progression after prior treatment with platinum-based chemotherapy and/or anti-PD-1/-PD-L1 immunotherapy now have access to an effective targeted therapy for the first time after decades of research. It is well tolerated and patient-friendly thanks to once-daily oral administration [1].

CodeBreaK 100: rapid and sustained response [2].

The open-label, single-arm, multicenter Phase II CodeBreaK 100 trial evaluated the efficacy and safety of Lumykras® in patients with locally advanced or metastatic KRAS G12C-mutated NSCLC whose disease had progressed on standard therapies. Patients with stable brain metastases were also included in the study. Patients received a once-daily oral dose of 960 mg Lumykras® until disease progression [2].

The primary endpoint was objective response rate (ORR), which was evaluated by an independent central committee according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria. The main secondary endpoints were duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and tolerability. With Lumykras® treatment, 37.1% of patients had an objective response (ORR; 95% CI: 28.6-46.2). Patients responded not only rapidly – within a median of 1.4 months – but also durably, with a median DOR of 11.1 months (95% CI: 6.9 – not evaluable). Lumykras® measured a decrease in tumor burden in 82.3% of patients (Figure); patients who responded to Lumykras® treatment showed an average tumor reduction of 60%. Treatment achieved a median (m)PFS of 6.8 months (95% CI, 5.1 – 8.2) [2].

In the 2-year long-term follow-up of 174 patients from the above-mentioned phase II and from the phase I study, the ORR increased to 40.7% (95% CI: 33.3 – 48.4) with an mDOR of 12.3 months (95% CI: 7.1-15.0). A DCR of 83.7% (95% CI: 77.3-88.9) was achieved and the mOS was 12.5 months (95% CI: 10.0 – 17.8). The OS rate after the first year was 50.8% (95% CI: 42.8-58.2) and 32.5% (95% CI: 25.0-40.2) of patients were still alive after the second year [3].

*KRAS=Kirstenrat sarcoma virus oncogene homologue 

Figure: Treatment response in the CodeBreaK 100 trial measured as best percent change from baseline in tumor burden in 121 evaluable patients. NE=not evaluable, PD=progressive disease, SD=stable disease, PR=partial response, CR=complete response. Adapted from [2]

 

Favorable tolerability profile also from the patient’s point of view [2,4]

The overall safety profile of Lumykras® proved to be well manageable. Treatment-related adverse events (TRAEs) occurred in 69.8% of patients and were mainly mild (≤ grade 2). The most common TRAEs reported with Lumykras® were diarrhea (32%), nausea (19%), and elevated liver enzymes (15% ASAT, 15% ALT). Treatment-related treatment discontinuations occurred in 7% of participants [2]. No new safety signals were registered in long-term follow-up [3]. Also, the majority of study participants reported no distress from adverse effects of Lumykras® treatment in a health-related quality of life questionnaire [4].

Conclusion

After more than 40 years of research, the approval of Lumykras® makes targeted therapy available for the first time to NSCLC patients with KRAS G12C mutation [1]. This shows promising clinical results in the CodeBreak100 trial and long-term follow-up compared with historical treatments in NSCLC [2, 3, 5]. The KRAS G12C inhibitor can achieve a rapid and sustained response even in heavily pretreated patients, while also having a favorable safety profile when used orally [1-3].  

 

Literature

 

1.                   Lumykras® (Sotorasib) Current Product Information at www.swissmedicinfo.ch.
2.              Skoulidis F et al. Sotorasib for lung cancers with KRAS p. G12C mutation. New England Journal of Medicine, 2021. 384(25): p. 2371-2381.
3.              Dy GK et al. Long-term Outcomes With Sotorasib in Pre-treated KRAS p.G12C Mutated NSCLC: 2-year Analysis of CodeBreaK 100 Presented at American Association for Cancer Research (AACR) Annual Meeting, April 8-13, 2022; New Orleans.
4.              Spira AI et al. Patient-reported outcomes (PRO) from the phase 2 CodeBreaK 100 trial evaluating sotorasib in KRAS p. G12C mutated non-small cell lung cancer (NSCLC). 2021, Wolters Kluwer Health.
5.              Horn L et al. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol, 2017. 35(35): p. 3924-3933.

 

References can be requested through professionals at medinfo-ch@amgen.com.

CH-510-0322-00007

Brief technical information Lumykras® 

Contribution online since 12.05.2022

Partner
  • amgenlogo_blue_lrg
Previous Article
  • Study report: Online survey

Molecular diagnostics in dermatology

  • Dermatology and venereology
  • Education
  • Genetics
  • RX
  • Studies
View Post
Next Article
  • SARS-CoV-2

In vitro study of the effects of a bacterial lysate in human epithelial tissue.

  • Education
  • General Internal Medicine
  • Infectiology
  • News
  • Pharmacology and toxicology
  • RX
  • Studies
View Post
You May Also Like
View Post
  • 7 min
  • Moderate to severe chronic hand eczema

Delgocitinib cream – first topical pan-JAK inhibitor approved in Switzerland

    • Allergology and clinical immunology
    • Dermatology and venereology
    • Education
    • Infectiology
    • Market & Medicine
    • Pharmacology and toxicology
    • RX
View Post
  • 9 min
  • Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CA)

Diagnosis at an early stage, prognostic classifications and outlook

    • Cardiology
    • Education
    • RX
    • Studies
View Post
  • 4 min
  • Case report: Drug-induced hepatitis

Rare side effect of tirzepatide therapy

    • Cases
    • Education
    • Endocrinology and Diabetology
    • Gastroenterology and Hepatology
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 4 min
  • Plea for sex-specific neurology

Migraine in men: underdiagnosed, underestimated, under-researched

    • Education
    • Neurology
    • RX
    • Studies
View Post
  • 4 min
  • Prurigo nodularis

Retrospective analyses of large data sets from everyday practice

    • Allergology and clinical immunology
    • Congress Reports
    • Dermatology and venereology
    • RX
View Post
  • 3 min
  • Public Health

Outpatient care in Switzerland: situation report

    • General Internal Medicine
    • Practice Management
    • Prevention and health care
    • RX
View Post
  • 5 min
  • Practice Management

Improved quality of care aims for satisfied patients

    • CME continuing education
    • General Internal Medicine
    • Practice Management
    • Prevention and health care
    • RX
    • Studies
View Post
  • 30 min
  • Chemsex - MSM, sex, chrystal meth & co.

Medical and psychosocial perspectives

    • CME continuing education
    • General Internal Medicine
    • Infectiology
    • Pharmacology and toxicology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • RX
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.